Skip to content
DataLookout
Menu

CONVICTIONNCT04805164

Evaluation of the Efficiency of the Bone Substitute Cerament-G Locally Delivering Gentamicin in the Treatment of Chronic Osteomyelitis of Long Bones

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 34 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 3 of 12 entries
    • Site details revised at 15 of 15 sites
  2. Notable Primary and study completion dates: Nov 14, 2026 to Nov 14, 2027
    • Study sites: 14 to 15
    v10
  3. Minor Site details revised at 1 of 14 sitesv9
  4. Minor Site details revised at 1 of 14 sitesv8
  5. Minor Site details revised at 1 of 14 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Site details revised at 2 of 14 sitesv6
  2. Minor Site details revised at 1 of 14 sitesv5
  3. Minor Site details revised at 1 of 14 sitesv4
  4. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary and study completion dates: Oct 2025 to Nov 14, 2026
    • Eligibility criteria expanded, about 9 words
    • Study sites: 0 to 14
    • Start date changed from estimate of Sep 2021 to Oct 14, 2021
  5. Minor Secondary endpoints expanded, about 53 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incremental Cost-Utility Ratio (ICUR) between the two treatments strategies for chronic long bone osteomyelitis
Timeframe: At 24 months (M24)

Secondary (12)

Recurrence of bone infection
Intraoperative and Postoperative complications
Repeated surgeries for complication
Proportion of patients with amputations
Bone healing and bone remodelling/consolidation
Show 7 moreShow less
Serious Adverse Events (SAEs) attributable to systemic antibiotic therapy.
Acute renal failure
Adverse Events related to the use of Cerament-G
Real cost
Estimated utility
Estimated incremental cost-effectiveness ratio
Budgetary impact analysis

Arms and interventions

Innovative strategyExperimental

usual medical and surgical care with corticotomy and use of a bone substitute (Cerament-G) delivering gentamicin locally (± skin and soft-tissue/muscle flap) and antibiotic therapy.

Reference strategyActive comparator

Medico-surgical usual care with corticotomy (± skin and soft-tissue/muscle flap), and antibiotic therapy.

Procedures: Corticotomy and use of the bone substitute : Cerament-G device., Corticotomy

Sites

15 sites in 1 country